Literature DB >> 24428591

Is polypharmacy always hazardous? A retrospective cohort analysis using linked electronic health records from primary and secondary care.

Rupert A Payne1, Gary A Abel, Anthony J Avery, Stewart W Mercer, Martin O Roland.   

Abstract

AIMS: Prescribing multiple medications is associated with various adverse outcomes, and polypharmacy is commonly considered suggestive of poor prescribing. Polypharmacy might thus be associated with unplanned hospitalization. We sought to test this assumption.
METHODS: Scottish primary care data for 180 815 adults with long-term clinical conditions and numbers of regular medications were linked to national hospital admissions data for the following year. Using logistic regression (age, gender and deprivation adjusted), we modelled the association of prescribing with unplanned admission for patients with different numbers of long-term conditions.
RESULTS: Admissions were more common in patients on multiple medications, but admission risk varied with the number of conditions. For patients with one condition, the odds ratio for unplanned admission for four to six medications was 1.25 (95% confidence interval 1.11-1.42) vs. one to three medications, and 3.42 (95% confidence interval 2.72-4.28) for ≥10 medications vs. one to three medications. However, this effect was greatly reduced for patients with multiple conditions; amongst patients with six or more conditions, those on four to six medications were no more likely to have unplanned admissions than those taking one to three medications (odds ratio 1.00; 95% confidence interval 0.88-1.14), and those taking ≥10 medications had a modestly increased risk of admission (odds ratio 1.50; 95% confidence interval 1.31-1.71).
CONCLUSIONS: Unplanned hospitalization is strongly associated with the number of regular medications. However, the effect is reduced in patients with multiple conditions, in whom only the most extreme levels of polypharmacy are associated with increased admissions. Assumptions that polypharmacy is always hazardous and represents poor care should be tempered by clinical assessment of the conditions for which those drugs are being prescribed.
© 2014 The British Pharmacological Society.

Entities:  

Keywords:  hospital admission; multimorbidity; polypharmacy; primary care

Mesh:

Year:  2014        PMID: 24428591      PMCID: PMC4093932          DOI: 10.1111/bcp.12292

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

1.  Relationship between polypharmacy and underprescribing.

Authors:  Mascha A J Kuijpers; Rob J van Marum; Antoine C G Egberts; Paul A F Jansen
Journal:  Br J Clin Pharmacol       Date:  2007-06-19       Impact factor: 4.335

2.  Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands.

Authors:  Anne J Leendertse; Antoine C G Egberts; Lennart J Stoker; Patricia M L A van den Bemt
Journal:  Arch Intern Med       Date:  2008-09-22

3.  Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems.

Authors:  Kirsten K Viktil; Hege S Blix; Tron A Moger; Aasmund Reikvam
Journal:  Br J Clin Pharmacol       Date:  2006-08-30       Impact factor: 4.335

4.  GPs' perceptions of multiple-medicine use in older patients.

Authors:  Janne Moen; Sara Norrgård; Karolina Antonov; J Lars G Nilsson; Lena Ring
Journal:  J Eval Clin Pract       Date:  2010-02       Impact factor: 2.431

5.  Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance.

Authors:  Cynthia M Boyd; Jonathan Darer; Chad Boult; Linda P Fried; Lisa Boult; Albert W Wu
Journal:  JAMA       Date:  2005-08-10       Impact factor: 56.272

6.  Polypharmacy and prescribing quality in older people.

Authors:  Michael A Steinman; C Seth Landefeld; Gary E Rosenthal; Daniel Berthenthal; Saunak Sen; Peter J Kaboli
Journal:  J Am Geriatr Soc       Date:  2006-10       Impact factor: 5.562

7.  The interaction of patient perception of overmedication with drug compliance and side effects.

Authors:  B G Fincke; D R Miller; A Spiro
Journal:  J Gen Intern Med       Date:  1998-03       Impact factor: 5.128

8.  Common comorbidity scales were similar in their ability to predict health care costs and mortality.

Authors:  Anthony J Perkins; Kurt Kroenke; Jürgen Unützer; Wayne Katon; John W Williams; Carol Hope; Christopher M Callahan
Journal:  J Clin Epidemiol       Date:  2004-10       Impact factor: 6.437

9.  Hospitalizations because of adverse drug reactions in elderly patients admitted through the emergency department: a prospective survey.

Authors:  Pascale Olivier; Lionel Bertrand; Marie Tubery; Dominique Lauque; Jean-Louis Montastruc; Maryse Lapeyre-Mestre
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

10.  Polypharmacy status as an indicator of mortality in an elderly population.

Authors:  Johanna Jyrkkä; Hannes Enlund; Maarit J Korhonen; Raimo Sulkava; Sirpa Hartikainen
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

View more
  63 in total

1.  Adverse drug reactions leading to urgent hospital admission in an elderly population: prevalence and main features.

Authors:  Consuelo Pedrós; Francesc Formiga; Xavier Corbella; Josep Maria Arnau
Journal:  Eur J Clin Pharmacol       Date:  2015-11-07       Impact factor: 2.953

2.  Determinants of change in polypharmacy status in Switzerland: the population-based CoLaus study.

Authors:  Nazanin Abolhassani; Julien Castioni; Pedro Marques-Vidal; Peter Vollenweider; Gérard Waeber
Journal:  Eur J Clin Pharmacol       Date:  2017-06-21       Impact factor: 2.953

3.  Older HIV-infected adults. Complex patients (III): Polypharmacy.

Authors:  Samuel F Freedman; Carrie Johnston; John J Faragon; Eugenia L Siegler; Tessa Del Carmen
Journal:  Eur Geriatr Med       Date:  2018-12-06       Impact factor: 1.710

4.  Editors' pick 2014.

Authors:  Yoon K Loke; Andrew A Somogyi; Albert Ferro; James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

5.  Polypharmacy patterns in the last year of life in patients with dementia.

Authors:  Rachel Denholm; Richard Morris; Rupert Payne
Journal:  Eur J Clin Pharmacol       Date:  2019-07-25       Impact factor: 2.953

6.  Is polypharmacy beneficial or detrimental for older adults with cardiometabolic multimorbidity? Pooled analysis of studies from Hong Kong and Europe.

Authors:  Johnny T K Cheung; Ruby Yu; Jean Woo
Journal:  Fam Pract       Date:  2020-11-28       Impact factor: 2.267

7.  The epidemiology of polypharmacy.

Authors:  Rupert A Payne
Journal:  Clin Med (Lond)       Date:  2016-10       Impact factor: 2.659

8.  Adverse drug events in patients with advanced chronic conditions who have a prognosis of limited life expectancy at hospital admission.

Authors:  Daniel Sevilla-Sanchez; Núria Molist-Brunet; Jordi Amblàs-Novellas; Pere Roura-Poch; Joan Espaulella-Panicot; Carles Codina-Jané
Journal:  Eur J Clin Pharmacol       Date:  2016-10-04       Impact factor: 2.953

9.  Prevalence and factors associated with polypharmacy in older people with cancer.

Authors:  Justin P Turner; Sepehr Shakib; Nimit Singhal; Jonathon Hogan-Doran; Robert Prowse; Sally Johns; J Simon Bell
Journal:  Support Care Cancer       Date:  2014-03-02       Impact factor: 3.603

10.  Factors affecting family physicians' drug prescribing: a cross-sectional study in Khuzestan, Iran.

Authors:  Mohammad Arab; Amin Torabipour; Abbas Rahimifrooshani; Arash Rashidian; Nayeb Fadai; Roohollah Askari
Journal:  Int J Health Policy Manag       Date:  2014-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.